Introduction {#s1}
============

Autism is a pervasive developmental disorder characterized by severe impairments in social skills, language and communication, as well as behavioral disturbances. There is growing public awareness of autism because rates of this disorder are thought to be rising [@pone.0009372-Newschaffer1]. The etiology of autism is still unknown and clues as to its cause are urgently needed.

Previous studies have reported that children with autism possess a higher number of genetic aberrations, including higher levels of chromosomal rearrangements [@pone.0009372-Vorstman1] and copy number variations [@pone.0009372-Christian1], [@pone.0009372-Marshall1], [@pone.0009372-Morrow1], [@pone.0009372-Sebat1], [@pone.0009372-Szatmari1]. These studies raise the possibility that there may be correlations to cancer, a disease in which chromosomal aberrations are known to play a role. Here, we report a study in which the incidence of cancer is compared to the prevalence of autism.

Beginning in 1975, the Individuals with Disabilities Education Act (IDEA) was passed, mandating that states report the number of children who undergo special education, subdivided according to a specified disability. In 1991, autism was added as a separate category by which states must report child count numbers. The IDEA database represents the sole national source of autism prevalence statistics in the U.S. Despite limitations, the IDEA data are the best available for estimates of autism prevalence in the U.S., and recent improvements have been made to this data system. For example, the methods by which states formally diagnose children with autism have been analyzed, and those states adhering to uniform criteria were identified [@pone.0009372-MacFarlane1]. Cancer statistics, by contrast, are collected with rigor, and the diagnosis is rarely in dispute and methods for determining cancer diagnosis are firmly established. Here, we present an analyses using both cancer and autism databases, incorporating information about state-level differences in autism diagnosis [@pone.0009372-MacFarlane1].

Results {#s2}
=======

State-Level Correlations of Autism Prevalence with Incidence of All Cancers {#s2a}
---------------------------------------------------------------------------

As depicted in [Figure 1](#pone-0009372-g001){ref-type="fig"}, we present Spearman rank correlations at the state level between autism prevalence (according to age groups and year reported) and cancer incidence (for the specific cancer type or group of cancers by gender and year). All possible combinations of autism and cancer data were correlated to avoid Type 1 bias, and the results were tabulated on a grid depicting the years for which autism or cancer data were reported ([Fig. 1](#pone-0009372-g001){ref-type="fig"}).

![Spearman rank correlations between annual cancer incidence and autism prevalence.\
Pairwise correlations were conducted between the annual incidence of adult cancers (all cancers combined) and the prevalence of autism. For each age group, 56 possible pairwise correlations depending on year were determined. For each year that state cancer incidence (from the CDC) and autism prevalence (from the IDEA) were reported, a two-tailed Spearman Rank correlation coefficient was determined. Significance was adjusted using Bonferroni\'s correction [@pone.0009372-Wright1] and shaded as indicated to facilitate visual inspection of the results. The CDC consolidates 24 anatomic sites for all female cancers and 22 anatomic sites for all male cancers.](pone.0009372.g001){#pone-0009372-g001}

Autism prevalence data before the year 2000 were omitted from these analyses because: 1) Data for ages 3--5 are unavailable prior to 2000; and 2) the latest diagnostic criteria for autism, DSM-IV TR, was introduced in 2000.

There are 56 different combinations by which autism prevalence (for a specific age group) and cancer incidence may be compared ([Fig. 1](#pone-0009372-g001){ref-type="fig"}). Some combinations yield a nominally significant correlation while others do not. Multiple correlations can introduce Type I error (acceptance of a false correlation), a common problem when relationships between two types of biological measurements are extrapolated [@pone.0009372-Curtin1]. Therefore, all the *p*-values were adjusted using the Bonferroni method of correction, a conservative technique for reducing Type I error. Thus, all calculated *p*-values were multiplied by 56 to yield an adjusted *p*-value not to exceed 1 (i.e. the *p*-value was adjusted to 1 if the Bonferroni correction yielded a value above 1) [@pone.0009372-Wright1]. Using this approach, Bonferroni-adjusted *p*-values \<0.05 are considered statistically significant (which corresponds to an initial, unadjusted *p*-value \<0.0009).

The correlations with autism prevalence conducted in [Fig. 1](#pone-0009372-g001){ref-type="fig"} utilized annual state-level incidence of all cancers according to gender. A pattern of significant correlations emerges from the data between all female cancers and autism, but not between all male cancers and autism.

We sought a method for reporting the Spearman rank correlations between annual cancer incidence and autism prevalence as a group, incorporating all Bonferroni-adjusted *p*-values (both nonsignificant and significant) to produce a combined overall *p*-value (summarized in [Table 1](#pone-0009372-t001){ref-type="table"}). One possibility is to record the percentage of nominally significant correlations (out of 56 correlations conducted per comparison, using the adjusted *p*-values). Another possibility is to use Fisher\'s inverse chi-square method [@pone.0009372-Fisher1], a well-established procedure for combining *p*-values obtained from independent observations, significant or otherwise. However, each individual *p*-value comes from observations that are not actually independent from one another, as will be described further in the [Discussion](#s3){ref-type="sec"}. Two methods for combining a group of dependent *p*-values were used: a modified version of Fisher\'s chi-square method that takes into account the relationship among the *p*-values [@pone.0009372-Brown1], and an improved Bonferroni procedure that rank *p*-values from the lowest to the highest values [@pone.0009372-Simes1]. As shown in [Table 1](#pone-0009372-t001){ref-type="table"}, the overall Bonferroni-adjusted *p*-value was nominally significant for correlations between autism prevalence and the incidence of all female but not male cancers. The *p*-values determined using Fisher\'s inverse chi-square method are very low, likely because the underlying assumption when using this method is that the *p*-values come from independent observations. Since this assumption is unlikely, the methods described by Brown or Simes are more appropriate for this analysis, and are reported in the subsequent Tables.

10.1371/journal.pone.0009372.t001

###### Correlations Between the Annual Incidence of All Adult Cancers and Autism Prevalence.

![](pone.0009372.t001){#pone-0009372-t001-1}

               Female Cancer Incidence correlated with Autism Prevalence   Male Cancer Incidence correlated with Autism Prevalence                                            
  ----------- ----------------------------------------------------------- --------------------------------------------------------- ---------------- ------------ --- --- --- -------
  3--5                                   21.4                                                  **7.3×10^−8^**                            0.040        **0.003**    0   1   1   0.047
  6--8                                   14.3                                                  **5.8×10^−6^**                            0.136        **0.005**    0   1   1   0.163
  9--11                                  42.9                                                  **1.6×10^−20^**                       **6.9×10^−7^**   **0.001**    0   1   1   0.126
  12--14                                 12.5                                                  **1.6×10^−7^**                            0.051        **0.002**    0   1   1   0.094
  15--17                                 19.6                                                  **6.8×10^−6^**                            0.142        **0.002**    0   1   1   0.166
  18--20                                 33.9                                                  **4.3×10^−11^**                         **0.004**      **0.0005**   0   1   1   0.064
  **3--21**                              42.9                                                  **3.3×10^−22^**                        **1×10^−7^**    **0.001**    0   1   1   0.110

\% *p*\<0.05 refers the to percentage of correlations out of the total number (56) that reach a nominal significance of *p*\<0.05 (Bonferroni-adjusted).

All possible combinations of pairwise correlations were performed between annual cancer incidence (all cancers combined) in females and males and the estimated prevalence of autism (as in [Fig. 1](#pone-0009372-g001){ref-type="fig"}). Each set of comparisons (autism vs cancer for a specific autism age group) consists of 56 correlations. Four ways of presenting significance are tabulated: 1) the percentage of correlations in which *p*\<0.05 (% *p*\<0.05; Bonferroni-adjusted); 2) an overall *p*-value using Fisher\'s inverse chi-square method (Fisher\'s P) [@pone.0009372-Fisher1]; 3) a modified inverse chi-square for dependent *p*-values (Brown\'s P) [@pone.0009372-Brown1]; and 4) a modified Bonferroni procedure to obtain an overall *p*-value (Simes\' P) [@pone.0009372-Simes1]. Nominally significant values (*p*≤0.01) are bolded.

A thorough analysis of each state\'s approach to diagnosing autism was recently published [@pone.0009372-MacFarlane1], thus allowing us to categorize states according to diagnostic method. Autism prevalence data obtained under the IDEA does not depend on DSM-IV-TR criteria (although it may for specific states), but rather, depends on the Code of Federal Regulations (CFR). Seventeen states and the District of Columbia apply a strict wording of the CFR to categorize children as being disabled by autism. The remaining states apply expanded criteria, including DSM-IV-TR or a broader definition to include all autism spectrum disorders. Four subdivisions of states ([Fig. 2](#pone-0009372-g002){ref-type="fig"}), were used to derive an overall *p*-value ([Table 2](#pone-0009372-t002){ref-type="table"}). Significance depends on both effect size and sample size, and by lowering sample size, significance is reduced. Despite this potential drawback to the analysis, nominal significance was still observed between autism prevalence and the incidence of all female cancers combined.

![Autism diagnostic criteria used by states.\
The number and identity (by postal state abbreviation) of states that adhere to strict wording in the CFR (CFR only) or expanded criteria (CFR expanded) to diagnose autism are indicated. The diagnosis of autism by CFR is included within the DSM-IV-TR definition, and those states that use the DSM-IV-TR theme are shown (DSM IV autism). States that expand their criteria to include autism spectrum disorder (ASD) represent the fourth criteria used (DSM IV expanded (ASD)).](pone.0009372.g002){#pone-0009372-g002}

10.1371/journal.pone.0009372.t002

###### Correlations Between the Annual Incidence of All Adult Cancers Combined and Autism Prevalence Subdivided by Method of Diagnosis.

![](pone.0009372.t002){#pone-0009372-t002-2}

                                         ALL         Expanded Criteria (CFR)   Expanded Criteria (DSM-IV)   Autism (DSM-IV)      CFR                               
  ------------------------ ------- ---------------- ------------------------- ---------------------------- ----------------- ----------- ---- ------- ---- ------- ----
  **All Female Cancers**    Brown   **1.0×10^−7^**             46                        0.395                    31            0.991     19     1     27     1     16
                            Simes     **0.001**                46                        0.004                    31          **0.010**   19   0.062   27   0.164   16
  **All Male Cancers**      Brown         1                    46                          1                      32              1       19     1     27     1     16
                            Simes       0.110                  46                        0.170                    32            0.136     19   0.529   27   0.767   16

Pairwise correlations were performed as described in [Table 1](#pone-0009372-t001){ref-type="table"} using two methods, Brown and Simes [@pone.0009372-Brown1], [@pone.0009372-Simes1], for combining dependent *p*-values. Autism prevalence data (ages 3--21) were obtained from groups of states selected on the basis of their criteria for diagnosing autism in all states or states subdivided by 4 groups of criteria ([Fig. 2](#pone-0009372-g002){ref-type="fig"}). P represents combined *p*-values for the Spearman correlations and bolded if P≤0.01. N represents the median number of states for which both autism and cancer data were available for analyses. Data are similar when the Pearson Correlation Coefficient is used ([Table S1](#pone.0009372.s001){ref-type="supplementary-material"}).

Correlations between Autism Prevalence and the Incidence of Specific Female and Male Cancers {#s2b}
--------------------------------------------------------------------------------------------

The same types of analyses were applied to 24 specific cancers for females and 22 cancers for males ([Tables 3](#pone-0009372-t003){ref-type="table"}, [Table 4](#pone-0009372-t004){ref-type="table"} [Table 5](#pone-0009372-t005){ref-type="table"} and [Table 6](#pone-0009372-t006){ref-type="table"}). Using Brown\'s method for combining *p*-values and the most restrictive diagnostic classification, CFR, significant correlations with autism prevalence was observed with the incidence of only one cancer, breast cancer *in situ* (*p*\<10^−10^; N = 16, [Table 3](#pone-0009372-t003){ref-type="table"}). All other correlations between autism prevalence (using the CFR classification) and the other female cancers ([Table 3](#pone-0009372-t003){ref-type="table"}) or male cancers ([Table 5](#pone-0009372-t005){ref-type="table"}) were nonsignificant using Brown\'s method for combining *p*-values. Simes\' method for combining *p*-values is less stringent, and other nominally significant correlations emerge using this test ([Tables 4](#pone-0009372-t004){ref-type="table"} & [6](#pone-0009372-t006){ref-type="table"}). Uterine cancer (Corpus and Uterus, NOS) displayed significant correlation with autism prevalence regardless of the diagnostic criteria used by state ([Table 4](#pone-0009372-t004){ref-type="table"}). The Spearman rank correlation generally provided similar results when compared to the Pearson product moment coefficient ([Tables S1](#pone.0009372.s001){ref-type="supplementary-material"}, [Table S2](#pone.0009372.s002){ref-type="supplementary-material"}, [Table S3](#pone.0009372.s003){ref-type="supplementary-material"}, [Table S4](#pone.0009372.s004){ref-type="supplementary-material"} and [Table S5](#pone.0009372.s005){ref-type="supplementary-material"}).

10.1371/journal.pone.0009372.t003

###### Correlations Between the Annual Incidence of Specific Female Adult Cancers and Autism Prevalence Subdivided by Method of Diagnosis, using Brown\'s P-value Method.

![](pone.0009372.t003){#pone-0009372-t003-3}

                                            ALL         Expanded Criteria (CFR)   Expanded Criteria (DSM-IV)   Autism (DSM-IV)    CFR                                       
  ---------------------------------- ----------------- ------------------------- ---------------------------- ----------------- ------- ---- ------- ---- ----------------- ----
  Brain and Other Nervous System             1                    44                          1                      29            1     19     1     25          1          15
  Breast, invasive                         0.108                  46                        0.914                    30          0.881   19     1     27          1          16
  Breast, in situ                     **1.5×10^−18^**             46                          1                      30            1     19   0.861   27   **7.5×10^−12^**   16
  Cervix Uteri                               1                    46                          1                      30            1     19     1     27          1          16
  Colon and Rectum                           1                    46                          1                      30            1     19     1     27          1          16
  Corpus and Uterus, NOS              **2.3×10^−12^**             46                          1                      30            1     19   0.638   27        0.990        16
  Esophagus                                  1                    34                          1                      22            1     15     1     20        0.979        13
  Hodgkin Lymphoma                           1                    37                          1                      24            1     16     1     21          1          14
  Kidney and Renal Pelvis                    1                    46                          1                      30            1     19     1     27          1          16
  Larynx                                     1                    32                          1                      21            1     14     1     18          1          11
  Leukemias                                  1                    46                          1                      30            1     19     1     27          1          16
  Liver and Intrahepatic Bile Duct           1                    38                          1                      24            1     16     1     22          1          14
  Lung and Bronchus                          1                    46                          1                      30            1     19     1     27          1          16
  Melanomas of the Skin                      1                    46                          1                      30            1     19     1     27          1          16
  Mesothelioma                               1                    13                          1                       9            1     6      1     7           1          4
  Myeloma                                    1                    43                          1                      28            1     18     1     25          1          16
  Non-Hodgkin Lymphoma                       1                    46                          1                      30            1     19     1     27          1          16
  Oral Cavity and Pharynx                    1                    45                          1                      29            1     19     1     26          1          16
  Ovary                                      1                    46                          1                      30            1     19     1     27          1          16
  Pancreas                                   1                    46                          1                      30            1     19   0.996   27          1          16
  Stomach                                    1                    43                          1                      27            1     18     1     25          1          16
  Thyroid                                    1                    46                          1                      30            1     19     1     27          1          16
  Urinary Bladder                          0.011                  46                          1                      30            1     19     1     27          1          16

Pairwise correlations were performed, as described in [Table 1](#pone-0009372-t001){ref-type="table"}, between state-level annual incidence for specific female cancers and autism prevalence (ages 3--21) from states selected on the basis of their criteria for diagnosing autism ([Fig. 2](#pone-0009372-g002){ref-type="fig"}). P represents combined *p*-values for Spearman correlations using Brown\'s method and bolded if P≤0.01. N represents the median number of states for which both autism and cancer data were available for analyses. Kaposi\'s sarcoma is omitted because there was insufficient data to conduct the analyses. Data are similar when the Pearson Correlation Coefficient is used ([Table S2](#pone.0009372.s002){ref-type="supplementary-material"}).

10.1371/journal.pone.0009372.t004

###### Correlations Between the Annual Incidence of Specific Female Adult Cancers and Autism Prevalence Subdivided by Method of Diagnosis, using Simes\' P-value Method.
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                                           ALL         Expanded Criteria (CFR)   Expanded Criteria (DSM-IV)   Autism (DSM-IV)      CFR                                       
  ---------------------------------- ---------------- ------------------------- ---------------------------- ----------------- ----------- ---- ----------- ---- ----------- ----
  Brain and Other Nervous System          0.795                  44                        0.613                    29            0.273     19     0.911     25     0.982     15
  Breast, invasive                      **0.002**                46                      **0.005**                  30          **0.003**   19     0.057     27     0.238     16
  Breast, *in situ*                   **2.2×10^−5^**             46                      **0.006**                  30            0.032     19   **0.002**   27   **0.001**   16
  Cervix Uteri                            0.064                  46                        0.843                    30            0.141     19     0.198     27     0.015     16
  Colon and Rectum                        0.174                  46                        0.740                    30            0.535     19     0.404     27     0.633     16
  Corpus and Uterus, NOS                **0.0004**               46                        0.015                    30            0.032     19   **0.004**   27   **0.010**   16
  Esophagus                             **0.006**                34                        0.193                    22            0.407     15     0.036     20   **0.003**   13
  Hodgkin Lymphoma                      **0.004**                37                        0.085                    24            0.497     16     0.027     21     0.053     14
  Kidney and Renal Pelvis                 0.719                  46                        0.460                    30            0.817     19     0.968     27     0.928     16
  Larynx                                  0.034                  32                        0.158                    21            0.479     14     0.242     18     0.322     11
  Leukemias                               0.506                  46                        0.977                    30            0.852     19     0.192     27     0.478     16
  Liver and Intrahepatic Bile Duct        0.860                  38                        0.981                    24            0.901     16     0.999     22     0.999     14
  Lung and Bronchus                       0.102                  46                        0.087                    30            0.063     19     0.966     27     0.981     16
  Melanomas of the Skin                   0.108                  46                        0.496                    30            0.588     19     0.752     27     0.410     16
  Mesothelioma                            0.479                  13                        0.106                     9            0.102     6      0.996     7       NA       4
  Myeloma                                 0.768                  43                        0.682                    28            0.923     18     0.997     25     0.976     16
  Non-Hodgkin Lymphoma                    0.013                  46                        0.012                    30            0.068     19     0.261     27     0.740     16
  Oral Cavity and Pharynx                 0.016                  45                        0.070                    29            0.290     19     0.100     26     0.301     16
  Ovary                                   0.689                  46                        0.983                    30            0.683     19     0.961     27     0.813     16
  Pancreas                                0.022                  46                        0.038                    30            0.854     19   **0.001**   27     0.030     16
  Stomach                                 0.065                  43                        0.150                    27            0.992     18     0.069     25     0.228     16
  Thyroid                                 0.994                  46                        0.992                    30            0.996     19     0.774     27     0.533     16
  Urinary Bladder                       **0.002**                46                        0.025                    30            0.023     19     0.110     27     0.020     16

Pairwise correlations were performed, as described in [Table 1](#pone-0009372-t001){ref-type="table"}, between state-level annual incidence for specific female cancers and autism prevalence (ages 3--21) from states selected on the basis of their criteria for diagnosing autism ([Fig. 2](#pone-0009372-g002){ref-type="fig"}). P represents combined *p*-values for Spearman correlations using Simes\' method and bolded if P≤0.01. N represents the median number of states for which both autism and cancer data were available for analyses. Kaposi\'s sarcoma is omitted because there was insufficient data to conduct the analyses. Data are similar when the Pearson Correlation Coefficient is used ([Table S3](#pone.0009372.s003){ref-type="supplementary-material"}).

10.1371/journal.pone.0009372.t005

###### Correlations between the Annual Incidence of Specific Male Adult Cancers and Autism Prevalence Subdivided by Method of Diagnosis, using Brown\'s P-value Method.
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                                         ALL      Expanded Criteria (CFR)   Expanded Criteria (DSM-IV)   Autism (DSM-IV)   CFR                         
  ---------------------------------- ----------- ------------------------- ---------------------------- ----------------- ----- ---- -------- ---- --- ----
  Brain and Other Nervous System          1                 45                          1                      31           1    19     1      27   1   15
  Colon and Rectum                        1                 46                          1                      31           1    19     1      27   1   16
  Esophagus                               1                 46                          1                      31           1    19     1      27   1   16
  Hodgkin Lymphoma                        1                 39                          1                      24           1    17     1      22   1   14
  Kaposi Sarcoma                          1                 14                          1                       9           1    7      1      7    1   5
  Kidney and Renal Pelvis                 1                 46                          1                      31           1    19     1      27   1   16
  Larynx                                  1                 44                          1                      28           1    19     1      25   1   16
  Leukemias                               1                 46                          1                      31           1    19     1      27   1   16
  Liver and Intrahepatic Bile Duct        1                 44                          1                      28           1    19     1      25   1   16
  Lung and Bronchus                       1                 46                          1                      31           1    19     1      27   1   16
  Melanomas of the Skin                   1                 46                          1                      31           1    19     1      27   1   16
  Mesothelioma                            1                 31                          1                      20           1    13     1      18   1   11
  Myeloma                                 1                 44                          1                      29           1    19     1      26   1   16
  Non-Hodgkin Lymphoma                  0.983               46                        0.9999                   31           1    19     1      27   1   16
  Oral Cavity and Pharynx                 1                 46                          1                      31           1    19     1      27   1   16
  Pancreas                                1                 46                          1                      31           1    19     1      27   1   16
  Prostate                                1                 46                          1                      31           1    19     1      27   1   16
  Stomach                                 1                 46                          1                      30           1    19   0.9944   27   1   16
  Testis                                  1                 44                          1                      30           1    19     1      26   1   15
  Thyroid                                 1                 42                          1                      27           1    18     1      24   1   15
  Urinary Bladder                     **0.002**             46                          1                      31           1    19     1      27   1   16

Pairwise correlations were performed, as described in [Table 1](#pone-0009372-t001){ref-type="table"}, between state-level annual incidence for specific male cancers and autism prevalence (ages 3--21) from states selected on the basis of their criteria for diagnosing autism ([Fig. 2](#pone-0009372-g002){ref-type="fig"}). P represents combined *p*-values for Spearman correlations using Brown\'s method and bolded if P≤0.01. N represents the median number of states for which both autism and cancer data were available for analyses. Data are similar when the Pearson Correlation Coefficient is used ([Table S4](#pone.0009372.s004){ref-type="supplementary-material"}).

10.1371/journal.pone.0009372.t006

###### Correlations between the Annual Incidence of Specific Male Adult Cancers and Autism Prevalence Subdivided by Method of Diagnosis, using Simes\' P-value Method.

![](pone.0009372.t006){#pone-0009372-t006-6}

                                         ALL      Expanded Criteria (CFR)   Expanded Criteria (DSM-IV)   Autism (DSM-IV)      CFR                                       
  ---------------------------------- ----------- ------------------------- ---------------------------- ----------------- ----------- ---- ----------- ---- ----------- ----
  Brain and Other Nervous System        0.175               45                        0.381                    31            0.210     19     0.832     27     0.803     15
  Colon and Rectum                      0.807               46                        0.996                    31            0.875     19     0.484     27     0.970     16
  Esophagus                             0.111               46                        0.277                    31            0.022     19     0.694     27     0.578     16
  Hodgkin Lymphoma                      0.044               39                        0.022                    24          **0.006**   17     0.253     22     0.087     14
  Kaposi Sarcoma                        0.992               14                        0.756                     9            0.152     7      0.931     7      0.407     5
  Kidney and Renal Pelvis               0.374               46                        0.414                    31            0.710     19     0.878     27     0.967     16
  Larynx                                0.487               44                        0.800                    28            0.633     19     0.914     25     0.866     16
  Leukemias                             0.996               46                        0.982                    31            0.991     19     0.995     27     0.924     16
  Liver and Intrahepatic Bile Duct      0.272               44                        0.140                    28            0.991     19     0.127     25     0.852     16
  Lung and Bronchus                     0.984               46                        0.992                    31            0.994     19     0.939     27     0.824     16
  Melanomas of the Skin                 0.123               46                        0.597                    31            0.999     19     0.227     27     0.165     16
  Mesothelioma                          0.013               31                        0.066                    20          **0.006**   13     0.188     18     0.053     11
  Myeloma                               0.963               44                        0.895                    29            0.737     19     0.994     26     0.731     16
  Non-Hodgkin Lymphoma                  0.013               46                        0.017                    31            0.047     19     0.039     27     0.159     16
  Oral Cavity and Pharynx               0.553               46                        0.978                    31            0.662     19     0.287     27     0.196     16
  Pancreas                              0.132               46                        0.378                    31            0.980     19     0.028     27     0.024     16
  Prostate                              0.381               46                        0.848                    31            0.395     19     0.999     27     0.809     16
  Stomach                               0.073               46                        0.367                    30            0.839     19   **0.004**   27   **0.008**   16
  Testis                                0.222               44                        0.310                    30            0.189     19     0.899     26     0.553     15
  Thyroid                               0.939               42                        0.985                    27            0.990     18     0.404     24     0.429     15
  Urinary Bladder                     **0.003**             46                        0.043                    31            0.030     19     0.018     27   **0.006**   16

Pairwise correlations were performed, as described in [Table 1](#pone-0009372-t001){ref-type="table"}, between state-level annual incidence for specific male cancers and autism prevalence (ages 3--21) from states selected on the basis of their criteria for diagnosing autism ([Fig. 2](#pone-0009372-g002){ref-type="fig"}). P represents combined *p*-values for Spearman correlations using Simes\' method and bolded if P≤0.01. N represents the median number of states for which both autism and cancer data were available for analyses. Data are similar when the Pearson Correlation Coefficient is used ([Table S5](#pone.0009372.s005){ref-type="supplementary-material"}).

Discussion {#s3}
==========

This study utilizes information from the IDEA and CDC database that may suggest shared risk factors between autism and specific cancers. Since both the autism and cancer database contain information for up to 50 states and the District of Columbia, the sample number for conducting correlations is high, representing a potentially useful resource for these preliminary ecological analyses. However, the utility of these analyses rests on the quality of the IDEA database.

One potential limitation is that of diagnostic substitution [@pone.0009372-Shattuck1], in which cases previously categorized as learning disabled or mental retardation in the 1990s may actually have been cases of autism. Although this may not be a problem in many states [@pone.0009372-Newschaffer2], autism as a separate category in the CFR did not occur until 1991. Another issue is that prevalence data before the age of 6 was not reported until the year 2000, probably reflecting continued refinement of the criteria for autism up to the year 2000. Our strategy to minimize this pitfall was to consider autism data only from the year 2000 forward in an effort to limit inaccurate counts due to diagnostic substitution and the changing definition of autism.

Perhaps the major criticism of the IDEA database concerns the wide range in the actual prevalence of autism in different states. As much as an eight-fold difference in autism prevalence rates has been reported between states [@pone.0009372-Mandell1]. Some states have been singled out for having unorthodox criteria (Oregon) [@pone.0009372-Laidler1], exceedingly high rates (Minnesota), a sudden 400% rise in rates from 2001--2002 (Massachusetts) [@pone.0009372-MacFarlane1], [@pone.0009372-Gernsbacher1], or idiosyncratic results (California) [@pone.0009372-Gernsbacher1]. A recent systematic study of the methods that states use to categorize autism does clarify these findings and may be helpful in extracting useful information from the IDEA database [@pone.0009372-MacFarlane1].

States are free to choose criteria for categorizing children with autism. School administrators and practitioners are not required to use the DSM-IV-TR to classify and to diagnose children, but they must use the diagnostic criteria outlined in the Code of Federal Regulations (CFR). Both the CFR and DSM-IV-TR recognize social interaction and communication as well as restrictive, repetitive, and stereotypical behavior, and thus the basic criteria for diagnosis are highly similar. However, the main difference between CFR and DSM-IV-TR is whether the child is disabled as a result of this diagnosis in order to qualify for special education under the autism category. Accordingly, the IDEA database underestimates autism prevalence, since it uses educational criteria for determining disability; high functioning individuals with autism who do not require special education are not counted [@pone.0009372-MacFarlane1].

Although states are free to choose their own eligibility criteria for special education services, they must do so as long as it meets or exceeds CFR guidelines. The legal code of every state and the District of Columbia were analyzed, along with inter-state variability [@pone.0009372-MacFarlane1]. As shown in [Fig. 2](#pone-0009372-g002){ref-type="fig"}, 17 states and the District of Columbia strictly abide by criteria used in the CFR. Interestingly, diagnosis using the CFR theme displayed high inter-rater reliability [@pone.0009372-MacFarlane1], and one could consider this category to represent a subset of autism as defined by DSM-IV-TR. The remaining 33 states expanded upon CFR criteria. Since the guidelines used in the CFR fall within those specified by DSM-IV-TR, states that abide by DSM-IV-TR include all those that use CFR plus an additional 13 states ([Fig. 2](#pone-0009372-g002){ref-type="fig"}). Autism Spectrum Disorder (ASD) includes other disorders related to autism, including Asperger\'s Syndrome. These "milder" disorders can account for up to 75% of the cases in some states, thus contributing greatly to the varied prevalence rates from state to state [@pone.0009372-Chakrabarti1].

An understanding of the different criteria that states use to classify children who qualify for special education under the category of autism greatly clarifies the findings made by previous researchers who have delved into this database. For instance, all the states for which unusual or high prevalence rates were cited (Oregon, Minnesota, Massachusetts, California) are states that have expanded the eligibility criteria for autism beyond CFR. Indeed, states that have expanded their criteria beyond CFR report substantially higher prevalence rates for autism [@pone.0009372-MacFarlane1]. Therefore, restricting the correlation analyses to those states that adhere strictly to wording used in the CFR would represent the most conservative way to use the IDEA database, even at the cost of reducing the sample size to about a third the number of states. The second least restrictive way is to use data from states that apply DSM-IV-TR to diagnose autism, but not autism spectrum disorder.

Data were analyzed using four subdivisions of states according to criteria used to diagnose children for eligibility for special education ([Fig. 2](#pone-0009372-g002){ref-type="fig"}). In evaluating significance, the Bonferroni\'s method for correcting *p*-values due to multiple comparisons is considered very conservative, because it raises Type II error (rejection of a true correlation) while reducing Type I error [@pone.0009372-Curtin1]. Two methods for calculating an overall *p*-value based on multiple Bonferroni-adjusted *p*-values were used. Brown\'s method [@pone.0009372-Brown1], which is a modification of Fisher\'s original inverse chi-square method [@pone.0009372-Fisher1], takes all *p*-values into account and determines if the log transformation of all the values fall within a chi-square distribution. Thus, multiple *p*-values need to show significance before the overall *p*-value becomes significant; a single *p*-value, even if very significant, will not result in an overall significance. A less conservative method, the Simes\' procedure [@pone.0009372-Simes1], determines if at least one *p*-value out of a set of *p*-values is significant. As can be observed from [Tables 3](#pone-0009372-t003){ref-type="table"}--[](#pone-0009372-t004){ref-type="table"} [](#pone-0009372-t005){ref-type="table"} [6](#pone-0009372-t006){ref-type="table"}, a few correlations meet significance using these conditions.

When the most restrictive criteria for selecting state-level autism data were used, states abiding by CFR strictly, and Brown\'s method for combining Bonferroni-adjusted *p*-values applied, only one correlation was significant: the correlation between autism prevalence and the incidence of *in situ* breast cancer (*p*\<10^−10^; N = 16). When a less conservative statistical method was applied (Simes\' procedure), correlations between autism and uterine cancer also emerged as consistently significant. By contrast, the great majority of correlations between specific forms of cancer and autism were negative. Although Type II error may have been increased as a result of these methods, it is appropriate in light of the controversial use of the IDEA database.

In conclusion, by using conservative statistical methods and a limited set of autism data from states using a uniform code of diagnosis, nominal statistical significance was observed in a few instances, notably for breast cancer and uterine cancer. In practice, it is not known whether the diagnosis of autism is truly uniform in individual school districts. Consequently, the results should be interpreted with caution, even if the *p*-values appear to be selective for these cancers and highly significant, as is the case here. Nonetheless, it is of interest that the cumulative exposure to estrogen from endogenous and external sources is an established risk factor for both breast [@pone.0009372-Yager1] and uterine [@pone.0009372-Amant1] cancer, the two cancers that appear to be most consistently correlated with autism. Some analyses suggest that mothers are carriers of mutations that predispose children to autism [@pone.0009372-Zhao1], and there is literature implicating germline mutations in autism [@pone.0009372-Reichenberg1], [@pone.0009372-Durkin1]. In this context, we suggest that investigating biomedical mechanisms to account for these epidemiological findings is warranted.

Materials and Methods {#s4}
=====================

Sources of Data {#s4a}
---------------

The number of children diagnosed with autism was collected for all states and ages between the years 2000--2007 from the U.S. Department of Education via the Individuals with Disabilities Act (IDEA) (<https://www.ideadata.org>). Six age groups were analyzed: 3--5, 6--8, 9--11, 12--14, 15--17, and 18--20 years; as well as the entire span of ages, 3--21. Autism prevalence separated by gender or before the age of 3 are not available. Annual resident population numbers by age and respective year (2000--2007) were obtained from the U.S. Census Bureau (<http://www.census.gov>), and used as the denominator to calculate the annual prevalence of autism in each state.

The age-adjusted annual incidence of specific cancers (standardized to the 2000 U.S. population) for males and females and for all states between the years 1999 and 2005 were obtained from the CDC (<http://apps.nccd.cdc.gov/uscs/>), the years presently available.

Statistical Analyses {#s4b}
--------------------

The Spearman rank correlation coefficients were calculated by comparing the prevalence of autism to the annual incidence of cancer, at the state level, throughout the U.S. This was done for each autism age group and year reported, and for each type of cancer and year reported. Significance was calculated using methods previously described [@pone.0009372-Zar1], and adjusted using the Bonferroni correction [@pone.0009372-Curtin1], [@pone.0009372-Wright1].

To obtain an overall significance or combined *p*-value for each set of correlations, three methods were used and compared: Fisher\'s inverse chi-square method [@pone.0009372-Fisher1], Brown\'s method for combining dependent *p*-values [@pone.0009372-Brown1] and Simes\' procedure [@pone.0009372-Simes1].

Supporting Information {#s5}
======================

###### 

Correlations Between the Annual Incidence of All Adult Cancers Combined and Autism Prevalence Subdivided by Method of Diagnosis. Pairwise correlations were performed as described in [Table 1](#pone-0009372-t001){ref-type="table"} using two methods, Brown and Simes [@pone.0009372-Brown1], [@pone.0009372-Simes1], for combining dependent p-values. Autism prevalence data (ages 3--21) were obtained from groups of states selected on the basis of their criteria for diagnosing autism in all states or states subdivided by 4 groups of criteria ([Fig. 2](#pone-0009372-g002){ref-type="fig"}). P represents combined p-values for the Pearson correlations and bolded if P≤0.01. N represents the median number of states for which both autism and cancer data were available for analyses.

(0.03 MB DOC)

###### 

Click here for additional data file.

###### 

Correlations Between the Annual Incidence of Specific Female Adult Cancers and Autism Prevalence Subdivided by Method of Diagnosis, using Brown\'s P-value Method. Pairwise correlations were performed, as described in [Table 1](#pone-0009372-t001){ref-type="table"}, between state-level annual incidence for specific female cancers and autism prevalence (ages 3--21) from states selected on the basis of their criteria for diagnosing autism ([Fig. 2](#pone-0009372-g002){ref-type="fig"}). P represents combined p-values for Pearson correlations using Brown\'s method and bolded if P≤0.01. N represents the median number of states for which both autism and cancer data were available for analyses. Kaposi\'s sarcoma is omitted because there was insufficient data to conduct the analyses.

(0.06 MB DOC)

###### 

Click here for additional data file.

###### 

Correlations Between the Annual Incidence of Specific Female Adult Cancers and Autism Prevalence Subdivided by Method of Diagnosis, using Simes\' P-value Method. Pairwise correlations were performed, as described in [Table 1](#pone-0009372-t001){ref-type="table"}, between state-level annual incidence for specific female cancers and autism prevalence (ages 3--21) from states selected on the basis of their criteria for diagnosing autism ([Fig. 2](#pone-0009372-g002){ref-type="fig"}). P represents combined p-values for Pearson correlations using Simes\' method and bolded if P≤0.01. N represents the median number of states for which both autism and cancer data were available for analyses. Kaposi\'s sarcoma is omitted because there was insufficient data to conduct the analyses.

(0.05 MB DOC)

###### 

Click here for additional data file.

###### 

Correlations Between the Annual Incidence of Specific Male Adult Cancers and Autism Prevalence Subdivided by Method of Diagnosis, using Brown\'s P-value Method. Pairwise correlations were performed, as described in [Table 1](#pone-0009372-t001){ref-type="table"}, between state-level annual incidence for specific male cancers and autism prevalence (ages 3--21) from states selected on the basis of their criteria for diagnosing autism ([Fig. 2](#pone-0009372-g002){ref-type="fig"}). P represents combined p-values for Pearson correlations using Brown\'s method and bolded if P≤0.01. N represents the median number of states for which both autism and cancer data were available for analyses.

(0.05 MB DOC)

###### 

Click here for additional data file.

###### 

Correlations Between the Annual Incidence of Specific Male Adult Cancers and Autism Prevalence Subdivided by Method of Diagnosis, using Simes\' P-value Method. Pairwise correlations were performed, as described in [Table 1](#pone-0009372-t001){ref-type="table"}, between state-level annual incidence for specific male cancers and autism prevalence (ages 3--21) from states selected on the basis of their criteria for diagnosing autism ([Fig. 2](#pone-0009372-g002){ref-type="fig"}). P represents combined p-values for Pearson correlations using Simes\' method and bolded if P≤0.01. N represents the median number of states for which both autism and cancer data were available for analyses.

(0.05 MB DOC)

###### 

Click here for additional data file.
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